ArriVent BioPharma (AVBP) Expected to Announce Quarterly Earnings on Thursday

ArriVent BioPharma (NASDAQ:AVBP) is anticipated to announce its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.8463) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 5, 2026 at 9:30 AM ET.

ArriVent BioPharma (NASDAQ:AVBP) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.09. On average, analysts expect ArriVent BioPharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

ArriVent BioPharma Trading Down 5.0%

Shares of NASDAQ:AVBP opened at $22.81 on Thursday. The stock has a market capitalization of $1.01 billion, a PE ratio of -5.17 and a beta of 0.99. ArriVent BioPharma has a 1 year low of $15.47 and a 1 year high of $27.22. The firm has a fifty day moving average price of $22.86 and a 200 day moving average price of $21.20.

Institutional Investors Weigh In On ArriVent BioPharma

Large investors have recently modified their holdings of the business. Russell Investments Group Ltd. raised its holdings in ArriVent BioPharma by 9,747.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,068 shares of the company’s stock worth $38,000 after buying an additional 2,047 shares during the period. BNP Paribas Financial Markets increased its stake in ArriVent BioPharma by 31.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,571 shares of the company’s stock valued at $56,000 after buying an additional 609 shares during the last quarter. Group One Trading LLC bought a new stake in ArriVent BioPharma during the fourth quarter worth about $57,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of ArriVent BioPharma by 696.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,258 shares of the company’s stock worth $60,000 after purchasing an additional 2,849 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in ArriVent BioPharma by 571.6% during the second quarter. Tower Research Capital LLC TRC now owns 6,669 shares of the company’s stock worth $145,000 after acquiring an additional 5,676 shares in the last quarter. 9.48% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Citigroup upped their target price on shares of ArriVent BioPharma from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Zacks Research upgraded shares of ArriVent BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, December 5th. Cantor Fitzgerald started coverage on shares of ArriVent BioPharma in a report on Monday, December 22nd. They issued an “overweight” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ArriVent BioPharma in a report on Wednesday, January 21st. Finally, HC Wainwright upped their price target on shares of ArriVent BioPharma from $42.00 to $44.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.78.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.